- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02213276
The Effect of Glucose on Bone - Direct og Indirect? (GLUBONE)
The Effect of Glucose on Bone - Direct or Indirect?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background
Previous studies have shown that Diabetes Mellitus type I (DMI) and II (DMII) is associated with an increased risk of bone fracture. Paradoxically DMII patients have higher Bone Mineral Density (BMD) than average, while DMI patients have lower BMD than average. Even the low BMD of DMI cannot fully explain the extent of fractures found. Known risk factors and BMD underestimate the risk of fracture amongst DM patients using the 10 year fracture risk tool 'Fracture Risk Assessment Tool' (FRAX). It is well-known that increased levels of biochemical bone markers predict low-energy fractures. However bone markers in DM patients show both heterogeneity and inconsistency. Because of this, the predictive value of bone markers is still uncertain in DM patients. Part of the pathology of DM is a higher blood glucose level than found in non-diabetics. This high level of blood glucose could potentially influence bone turnover and thereby bone markers. It is, however, still uncertain whether glucose per se influences the fracture risk of DM patients. Among young healthy individuals, an Oral Glucose Tolerance Test (OGTT) reduces the concentration of both resorptive and formative bone markers. This reduction can be counteracted by the somatostatin analogue, octreotide. Therefore the effect of glucose on bone markers may be indirect and linked to gut hormone release. It may also be caused by a direct effect on osteocytes or a change in the chemical configuration of bone markers, which render them undetectable by standard assays. To examine this, we have conducted preliminary in vitro trials where glucose was added to serum. This does not change the level of bone markers and it is therefore unthinkable that glucose per se affects the assay or causes changed bone marker configuration. The effect of an Intravenous Glucose Tolerance Test (IVGTT) on bone markers has never been examined. Subcutaneous and parenteral injection of the gut hormone glucagon-like peptide 2 (GLP-2) dose-dependently reduces resorptive bone markers, while parenteral GLP-2 entails no change in formative bone markers. This shows that GLP-2 has an uncoupled effect on bone turnover, where resorption is inhibited, and formation remains the same.
There is an association between bone turnover, inflammation and glucose. Chronic inflammation in patients with inflammatory bowel disease increases bone resorption through an increase in the Receptor Activator of Nuclear factor Kappa beta Ligand/Osteoprotegrin (RANKL/OPG) ratio, and the same may be the case in DMII. Human endothelial cells augment production of the inflammatory marker MCP-1 when glucose levels are continuously elevated. RANKL also induces MCP-1 production in human osteoclasts. An in vitro trial shows, that at blood glucose level of 24 mM, osteoblasts increases expression of RANKL, production of inflammatory markers, including MCP-1, and expression of mRNA for the formative bone marker osteocalcin. It has not yet been examined whether MCP-1 correlates with formative and resorptive bone markers in vivo. It is therefore still uncertain whether glucose has a direct effect on bone turnover or an indirect effect via. either GLP-2 or inflammatory processes.
Aim
The aim of this project is to examine whether IVGTT reduces bone marker levels in the same degree as OGTT does. Also, we examine whether the effect of the glucose load is direct or indirect through either GLP-2 or inflammatory processes reflected by inflammatory markers.
Perspective
This project will determine whether the effect of glucose on bone markers is direct or indirect. This knowledge can then be used to explore whether glucose is 'the missing link' in the present fracture prediction score for DM patients.
Methods
In this project 12 healthy male subjects will undergo both oral glucose tolerance test and intra venous glucose tolerance test. During the tests bone markers will be measured at different time intervals and compared to each other. Using these methods it is possible to distinguish whether glucose acts directly on bone and bone markers or through an intestinal or inflammatory pathway. Subjects will be recruited from advertising. After signing a consent form, subjects will fill out a questionaire concerning lifestyle (smoking, alcohol, diet and exercise), previous fracture and familiar disposition to DM, osteoporosis and thyroid disease. Bloodpressure, height and weight will be measured.
Statistics
Paired t-test and repeated measurement analysis will be used for the statistical analyses, as well as linear and logistical regression for adjustment for potential confounders.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Aarhus C
-
Aarhus, Aarhus C, Denmark, 8000
- Department of Endocrinology and Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males
- Aged 20 - 50 years
Exclusion Criteria:
- Chronic diseases, including diabetes, but not allergies
- Daily medication use
- Daily dietary supplement use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy males
Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
|
At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water.
Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
In this intervention, the participant needs to have two intravenous accesses.
In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test.
In order to do this, blood glucose is measured every 5 minutes.
At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The resorptive bone marker S-CTX.
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
This outcome will be measured for both the oral glucose tolerance test and the intravenous glucose tolerance test, in order to detect differences in bone marker status.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
The formative bone marker S-P1NP
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
This outcome will be measured for both the oral glucose tolerance test and the intravenous glucose tolerance test, in order to detect differences in bone marker status.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
S-NTX
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Same as for primary outcome.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
S-OC
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Same as for primary outcome.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
RANKL.
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Same as for primary outcomes.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Inflammatory markers.
Time Frame: Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Same as for primary outcomes.
|
Change from baseline (at 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2014-e1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Markers
-
Hadassah Medical OrganizationWithdrawnInflammatory Markers | PulpotomyIsrael
-
IVI MadridCompletedInflammatory Markers | Androgen Profile | IVF OutcomeSpain
-
Hamad Medical CorporationRecruitingInflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator DecannulationQatar
-
Colgate PalmoliveCompletedPeriodontal Disease | Systemic Inflammatory Markers
-
University of Campania "Luigi Vanvitelli"RecruitingBirth Weight | Systemic Inflammation Markers | Combined Systemic Inflammatory IndicesItaly
-
St. Elizabeth Cancer Institute, SlovakiaF.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica; Louis Pasteur...Not yet recruiting
-
Bispebjerg HospitalCompleted
-
Rockefeller UniversityCompletedObesity | Ketosis | Time Restricted Feeding | Inflammatory Markers | Glycemic VariationUnited States
-
Hospital AvicenneRoche Diagnostics; ProBayes; Biorance Laboratoires RéunisCompletedBiological Markers | Inappropriate PrescribingFrance
-
Cairo UniversityCompletedInsulin Resistance | Inflammatory MarkersEgypt
Clinical Trials on Oral Glucose Tolerance Test (OGTT)
-
Glostrup University Hospital, CopenhagenCompletedDiabetes MellitusDenmark
-
NYU Langone HealthCompletedGlucose Metabolism Disorders | Diabetes Mellitus | Prediabetic State | Diabetes, GestationalUnited States
-
Shanghai First Maternity and Infant HospitalCompletedPregnancy | Gestational Diabetes Mellitus | Thyroid Function Tests
-
University of AarhusCompletedGestational DiabetesDenmark
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesDenmark, Japan
-
Cedars-Sinai Medical CenterUnknownAcromegalyUnited States
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Rockefeller UniversityCompletedGlucose Metabolism DisorderUnited States
-
Western Galilee Hospital-NahariyaNot yet recruitingObesity | Polycythemia | Obesity, Morbid | Gestational Diabetes Mellitus in Pregnancy | Neonatal Jaundice | Macrosomia, Fetal | Hypoglycemia Neonatal | Dystocia, ShoulderIsrael
-
Hitit UniversityEskisehir Osmangazi UniversityCompleted